Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.54 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.54 |
| ▸ | DRD4 | P21917 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14572057 | 0.84 | PRMT5 (0.55) | PRMT5WDR77DRD4MAPK1MEN1 | |
| SCHEMBL29502671 | 0.77 | PRMT5 (0.81) | PRMT5WDR77LMNAMAPTGAA | |
| SCHEMBL28692108 | 0.77 | PRMT5 (0.81) | PRMT5WDR77LMNAMAPTGAA | |
| SCHEMBL28711197 | 0.77 | PRMT5 (0.81) | PRMT5WDR77LMNAMAPTGAA | |
| SCHEMBL29481804 | 0.77 | PRMT5 (0.81) | PRMT5WDR77LMNAMAPTGAA | |
| SCHEMBL5633933 | 0.74 | MAPT (0.37) | LMNAMAPTKDM4EGAAMAPK1 | |
| SCHEMBL5633929 | 0.74 | MAPT (0.37) | LMNAMAPTKDM4EGAAMAPK1 | |
| SCHEMBL28737820 | 0.73 | PRMT5 (0.74) | PRMT5WDR77LMNAMAPTGAA | |
| SCHEMBL28290354 | 0.73 | PRMT5 (0.74) | PRMT5WDR77LMNAMAPTGAA | |
| SCHEMBL29650357 | 0.73 | PRMT5 (0.74) | PRMT5WDR77LMNAMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377583-A1 | NOVEL TRICYCLIC HYDROXY CARBOXAMIDES AND DERIVATIVES THEREOF; TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | Wyeth (US) | 2004-01-07 | — | — | EP | claimed |
| WO-2002083680-A1 | NOVEL TRICYCLIC HYDROXY CARBOXAMIDES AND DERIVATIVES THEREOF TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | claimed |
| US-7186718-B2 | Piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2007-03-06 | — | — | US | disclosed |
| EP-1421082-B1 | PIPERIDINYL-MORPHOLINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2006-01-11 | — | — | EP | disclosed |
| US-20040204408-A1 | Piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity | ASTRAZENECA AB (SE) | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204408-A1 | Piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity | CCR5, CCR2, CXCR2 | PRMT5 543/4885WDR77 3555/4885DRD4 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.